Alterity Therapeutics Files 6-K, Incorporates by Reference
Ticker: PRNAF · Form: 6-K · Filed: Oct 23, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, agm, registration-statement
TL;DR
ALTERITY THERAPEUTICS LTD files 6-K, links to AGM notice in S-8/F-3 filings.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on October 23, 2024, to incorporate by reference into several of its existing Registration Statements on Form S-8 and Form F-3. The filing includes a Notice of Annual General Meeting and Explanatory Memorandum as Exhibit 99.1.
Why It Matters
This filing is procedural, incorporating previous documents into active registration statements, which is important for ongoing securities offerings and compliance.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previously issued documents, posing no new immediate risks.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- Form S-8 (document) — Registration Statement
- Form F-3 (document) — Registration Statement
- October 23, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to incorporate by reference the Notice of Annual General Meeting and Explanatory Memorandum (Exhibit 99.1) into Alterity Therapeutics Limited's existing Registration Statements on Form S-8 and Form F-3.
Which specific registration statements are being updated by this filing?
This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is included as Exhibit 99.1 in this filing?
Exhibit 99.1 is the Notice of Annual General Meeting and Explanatory Memorandum.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is October 23, 2024.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office address is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 192 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2024-10-23 08:00:08
Filing Documents
- ea0218378-6k_alterity.htm (6-K) — 14KB
- ea021837801ex99-1_alterity.htm (EX-99.1) — 272KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- ex99-1_002.jpg (GRAPHIC) — 2KB
- ex99-1_003.jpg (GRAPHIC) — 1961KB
- ex99-1_004.jpg (GRAPHIC) — 322KB
- 0001213900-24-089788.txt ( ) — 3441KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notice of Annual General Meeting and Explanatory Memorandum 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 23, 2024 2